298 related articles for article (PubMed ID: 34561270)
1. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
Singh K; Batich KA; Wen PY; Tan AC; Bagley SJ; Lim M; Platten M; Colman H; Ashley DM; Chang SM; Rahman R; Galanis E; Mansouri A; Puduvalli VK; Reardon DA; Sahebjam S; Sampson JH; Simes J; Berry DA; Zadeh G; Cloughesy TF; Mehta MP; Piantadosi S; Weller M; Heimberger AB; Khasraw M
Clin Cancer Res; 2022 Feb; 28(4):585-593. PubMed ID: 34561270
[TBL] [Abstract][Full Text] [Related]
2. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
4. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
5. Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive mechanisms in glioblastoma.
Nduom EK; Weller M; Heimberger AB
Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii9-vii14. PubMed ID: 26516226
[TBL] [Abstract][Full Text] [Related]
7. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
Das S; Dash BS; Premji TP; Chen JP
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445721
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma.
Zhou S; Huang Y; Chen Y; Liu Y; Xie L; You Y; Tong S; Xu J; Jiang G; Song Q; Mei N; Ma F; Gao X; Chen H; Chen J
Nat Commun; 2023 Jan; 14(1):435. PubMed ID: 36702831
[TBL] [Abstract][Full Text] [Related]
11. Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):266-269. PubMed ID: 35976319
[TBL] [Abstract][Full Text] [Related]
12. The network of immunosuppressive pathways in glioblastoma.
Mangani D; Weller M; Roth P
Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
14. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
17. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
19. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
